EGFR and breast cancer: In particular, among European women diagnosed with breast cancer, the core basal phenotype (CBP; ER-negative, PR-negative, HER2-negative, cytokeratin 5-positive and/or epidermal growth factor receptor-positive) was associated with a greater average number of acini per TDLU and larger average TDLU diameter compared with luminal A cancers [10].